Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Synairgen makes progress with lung drug

Lung drug developer says tests showed success in treating idiopathic pulmonary fibrosis
Synairgen makes progress with lung drug
Syanairgen hopes to progress one of the Pharmaxis enzyme inhibitors to phase one trials next year

Respiratory drug group Synairgen plc (LON:SNG) has taken a step forward in developing a treatment for a fatal lung disease.

Synairgen announced positive results from its ongoing collaboration with Pharmaxis to develop a lysyl oxidase type 2 enzyme (LOXL2) inhibitor as a novel treatment for idiopathic pulmonary fibrosis (IPF).

IPF results from the build-up of scar tissue, or fibrosis, in the lungs, which prevents normal uptake of oxygen. There are more than 100,000 IPF sufferers in the US alone.

The results of the experiments showed that the Pharmaxis enzyme inhibitors, by inhibiting LOXL2, could reduce cross-linking of collagen fibres - which results in fibrosis.

Synairgen will now focus on the pharmacology of the inhibitors and expects to progress one of them to phase one clinical trials in 2017.

Chief executive Richard Marsden said: "We are very pleased with the progress made with this collaboration and are excited by these results.

"We look forward to updating the markets with further progress over the coming months."

Meanwhile, Synairgen announced losses from operations for the year to December 31 of £2.61mln against profits of £1.09mln a year ago.

The profit a year ago was driven by a one-off upfront licensing payment from AstraZeneca PLC (LON:AZN) of £4.25mln.

The group said its current funds would support the ongoing search and identification of new potential molecule opportunities.

Chairman Simon Shaw said: "We are pleased with the progress made this year across our collaborations and in screening new opportunities.

"Our primary asset, AZD-9412, is being progressed through the clinic by AstraZeneca with results expected in 2017.

"Our strong balance sheet positions us well for progressing further collaborative programmes during the coming year."

Phil-Waller.jpg
Why Invest In Synairgen plc? Read More Here

Register here to be notified of future SNG Company articles
View full SNG profile

Synairgen plc Timeline

Related Articles

newspaper with word cancer magnified
January 30 2017
The start of 2017 has seen some good trial results for its skin cancer treatment, as well as a collaboration deal that will accelerate the development of its lung cancer drug
shutterstock_327930536.jpg
December 02 2016
Life sciences firm ValiRx is poised for a busy year ahead as it progresses its lead drugs...
viagra2.jpg
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.